BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratajczak M, Gaweł D, Godlewska M. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update. Int J Mol Sci 2021;22:11829. [PMID: 34769260 DOI: 10.3390/ijms222111829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Safdar MA, Aslam RMN, Shakeel A, Shiza, Waqar M, Jmail A, Mehmood MH, Gul H. Cyanidin as potential anticancer agent targeting various proliferative pathways. Chem Biol Drug Des 2023;101:438-52. [PMID: 36326796 DOI: 10.1111/cbdd.14173] [Reference Citation Analysis]
2 Højer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int J Mol Sci 2023;24. [PMID: 36768635 DOI: 10.3390/ijms24032312] [Reference Citation Analysis]
3 Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, Antonelli A, Fallahi P, Ferrari SM. Molecular features of aggressive thyroid cancer. Front Oncol 2022;12:1099280. [PMID: 36605433 DOI: 10.3389/fonc.2022.1099280] [Reference Citation Analysis]
4 Li G, Chen W, Gong Y, Wei T, Gong R, Zhu J, Li Z, Lei J. Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma. J Pers Med 2022;12. [PMID: 36556238 DOI: 10.3390/jpm12122017] [Reference Citation Analysis]
5 Boudin L, Morvan JB, Thariat J, Métivier D, Marcy PY, Delarbre D. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. Curr Oncol 2022;29:7718-31. [PMID: 36290887 DOI: 10.3390/curroncol29100610] [Reference Citation Analysis]
6 Li J, Zhang Y, Sun F, Xing L, Sun X. Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer. Front Endocrinol 2022;13:980582. [DOI: 10.3389/fendo.2022.980582] [Reference Citation Analysis]
7 Kaliszewski K, Ludwig M, Ludwig B, Mikuła A, Greniuk M, Rudnicki J. Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years? Cancers (Basel) 2022;14:3643. [PMID: 35892901 DOI: 10.3390/cancers14153643] [Reference Citation Analysis]
8 Macerola E, Poma AM, Vignali P, Proietti A, Ugolini C, Torregrossa L, Basolo A, Elisei R, Santini F, Basolo F. Predictive Biomarkers in Thyroid Cancer. Front Oncol 2022;12:901004. [DOI: 10.3389/fonc.2022.901004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Qu F, Bu H, Yang L, Liu H, Xie C. Analysis of the Rehabilitation Efficacy and Nutritional Status of Patients After Endoscopic Radical Thyroidectomy by Fast Track Surgery Based on Nutritional Support. Front Surg 2022;9:897616. [DOI: 10.3389/fsurg.2022.897616] [Reference Citation Analysis]
10 Oh JM, Rajendran RL, Gangadaran P, Hong CM, Jeong JH, Lee J, Ahn B. Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers. Cancers 2022;14:1782. [DOI: 10.3390/cancers14071782] [Reference Citation Analysis]
11 Silaghi H, Lozovanu V, Georgescu CE, Pop C, Nasui BA, Cătoi AF, Silaghi CA. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer. Int J Mol Sci 2022;23:3470. [PMID: 35408830 DOI: 10.3390/ijms23073470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ibrahiem AT, Fawzy MS, Abdulhakim JA, Toraih EA. GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis. IJGM 2022;Volume 15:2929-44. [DOI: 10.2147/ijgm.s354108] [Cited by in F6Publishing: 1] [Reference Citation Analysis]